Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva Dose Escalation to Rash in Metastatic Pancreatic Cancer
NCT00652366Phase 2Completed
- Sponsor
- Roche
- Start
- May 2008
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 2, randomised, open-label trial of erlotinib in pancreatic cancer (PC) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants Who Died up to 46 months and Overall Survival up to 46 months. Started May 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00652366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00652366.